Print

Infinity Pharmaceuticals Inc. (INFI) Reports Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 Across a Broad Range of Blood Cancers at the 12th International Conference on Malignant Lymphoma  
6/24/2013 8:00:16 AM

Sign up for the free GenePool newsletter today!

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Hodgkin lymphoma (HL) and T-cell lymphomas.

Help employers find you! Check out all the jobs and post your resume.

//-->